Sanofi Launches 2025 Global Stock Plan for Employees
Sanofi Unveils 2025 Global Employee Shareholding Plan, Reinforcing Long-Term Workforce Commitment Sanofi has officially launched Action 2025, the latest installment of its long-running global employee shareholder program. Opening on June…
Vividion and Bayer Advance Oncology Pipeline with WRN Inhibitor
Vividion and Bayer Expand Oncology Pipeline with Exclusive Rights to Clinical-Stage WRN Inhibitor VVD-214 Vividion Therapeutics,a clinical-stage biopharmaceutical company and wholly owned subsidiary of Bayer AG, has announced a significant…
CPR Training Turns Heroic: Walgreens Manager Revives Daughter in Emergency
CPR Training Turns Walgreens Manager into a Hero Dad: How Quick Thinking Saved His Daughter’s Life Adyn Romahn was enjoying a quiet moment at home in Great Bend, Kansas, watching…
ODA Cuts Deepen the Neglect of Tropical Diseases
Neglected Again: ODA Cuts Threaten Global Progress on Tropical Diseases Neglected tropical diseases (NTDs) continue to plague over a billion people around the world, predominantly affecting vulnerable populations in low-resource…
Primary Health Care on the Rise Worldwide: Now Is the Time to Stand Together
Global Drive for Primary Health Care Gains Ground at World Health Assembly: A Unified Call to Action In a powerful demonstration of international unity and purpose, global health leaders convened…
Legend Biotech Reports Landmark 5-Year CARVYKTI Data at ASCO 2025
Legend Biotech Unveils Landmark Five-Year Survival Data for CARVYKTI® in Relapsed/Refractory Multiple Myeloma at ASCO 2025 Legend Biotech Corporation,a global leader in cell therapy innovation, presented groundbreaking long-term data at…
FDA Approves Third Use for Bayer’s Nubeqa in Advanced Prostate Cancer
Bayer’s Nubeqa Secures Third FDA Approval, Expanding Prostate Cancer Treatment Landscape Bayer has announced that the U.S. Food and Drug Administration (FDA) has granted approval for a third indication of…
EC Approves ADCETRIS for Newly Diagnosed Advanced Hodgkin Lymphoma
Takeda Secures European Commission Approval for ADCETRIS® in Combination with ECADD as a New Frontline Therapy for Adults with Advanced-Stage Hodgkin Lymphoma Takeda has announced a major milestone in the…
ASCO: Sarclisa Data Backs Subcutaneous On-Body Delivery
ASCO 2025: Subcutaneous Sarclisa with On-Body Injector Shows Promise in Multiple Myeloma Treatment At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, Sanofi presented promising data from two…
AbbVie Opens 2nd Annual Migraine Career Catalyst Award Contest
AbbVie Launches Second Annual Migraine Career Catalyst Award to Empower People with Migraine in Pursuit of Their Professional Dreams Pharmaceutical company AbbVie has announced the return of its AbbVie Migraine…
Tecentriq + Lurbinectedin Boost Survival in Extensive-Stage SCLC
Roche Announces Positive Phase III IMforte Study Results: Tecentriq Combined with Lurbinectedin Demonstrates Significant Survival Benefit in Extensive-Stage Small Cell Lung Cancer Roche today reported promising outcomes from the pivotal…
Lilly Unveils First Clinical Data for Next-Gen FRα ADC in Platinum-Resistant Ovarian Cancer at ASCO 2025
Eli Lilly Presents Promising Phase 1 Data for Investigational FRα-Targeting ADC in Platinum-Resistant Ovarian Cancer at ASCO 2025 Eli Lilly and Company has announced encouraging new Phase 1 clinical data…